After a positive evaluation by the reviewers and the jury, we are delighted to announce that CNATM has now been officially approved for its second funding period (2026-2029). CNATM continues to be the only national BMFTR cluster focused on nucleic acid therapeutics.

We are grateful for the continued support from BMFTR and look forward to continuing our projects over the next three years — with the goal of further strengthening Munich as an international hub for nucleic‑acid‑based research.

This marks a strong signal for innovation and the medicine of the future.
A heartfelt thank‑you goes to our partners from the first funding phase and to all new partners joining us in the second phase.